The US Pen Needles Market is projected to grow from USD 0.93 billion in 2026 to USD 1.53 billion by 2031, registering a CAGR of 10.4% during the forecast period. Growth is being driven by the expanding insulin-dependent population, broader adoption of injectable GLP-1 therapies, and the continued shift toward patient-centric, home-based diabetes management.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9759386
What Is Fueling Market Expansion?
The increasing prevalence of diabetes, an aging population, and sedentary lifestyles are expanding the number of insulin users across the US. At the same time, insulin pen systems have become the preferred delivery format due to their convenience, dosing accuracy, and ease of self-administration.
High replacement frequency—often daily—creates consistent, recurring demand. Innovations such as fine-gauge needles, shorter lengths (5mm), low-trauma tips, and safety-engineered designs are further enhancing patient comfort and adherence.
Additionally, the rapid expansion of telehealth, e-prescribing, and digital pharmacy platforms is strengthening direct-to-patient fulfillment models, reinforcing long-term market growth.
Market Pressures: Pricing, Reimbursement, and Therapy Shifts
Despite strong demand fundamentals, the market faces margin pressures due to:
1. Intense price competition and commoditization
2. Reimbursement variability across payers
3. Preference for lower-cost standard needles in formularies
4. Broader adoption of non-insulin therapies, including GLP-1–based treatments for diabetes and weight management
5. Policy initiatives aimed at lowering insulin prices
These dynamics could moderate volume growth or compress margins. However, opportunities remain in premiumization, smart/connected disposables, OEM supply partnerships with insulin pen manufacturers, subscription-based refill models, and value-based contracting strategies.
Standard Pen Needles Lead by Type
The standard pen needles segment accounts for the largest share of the U.S. pen needles market, due to their broad compatibility with almost any insulin pen, thereby making them the first choice across all retail pharmacies, hospitals, and mail-order channels. Standard needles align with the reimbursement policies and formulary preferences of payers, who are often inclined toward low-cost, high-volume consumables. These needles are familiar to patients and clinicians alike, requiring minimal training, which facilitates more consistent adherence. Standard needles are manufactured in bulk by major suppliers, which guarantee their availability and price stability, thereby further endorsing procurement preference. Together, all these factors create sustained, high-volume demand that puts standard pen needles in the strongest position of dominance for the US market.
Online Purchase Segment to Register Fastest Growth
The segment of online purchases is expected to show the largest CAGR in the US pen needles market, owing to the rising adoption of e-pharmacies, subscription refill modes, and direct-to-patient delivery services, which meet the high-frequency replacement requirements of insulin users. Increased levels of comfort with digital health platforms, the extension of telemedicine prescribing, and the broader acceptance of mail-order pharmacies by insurance packages are driving shifts from retail stores to online fulfillment. The strategy implementation by large players such as Amazon, Walmart, and major pharmacy chains toward same-day and auto-refill services reduces the consumer’s burden and increases price visibility for their products.
Request For Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=9759386
Competitive Landscape
Leading companies are pursuing organic and inorganic growth strategies, including product innovation, geographic expansion, strategic collaborations, and acquisitions.
Prominent players in the US pen needles market include: Embecta Corp. (US), Novo Nordisk A/S (Denmark), MTD Medical Technology and Devices (Italy), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US).
Strategic Outlook
The US pen needles market sits at the intersection of chronic disease management, payer economics, and digital health transformation.
Executives must balance scale-driven cost efficiency with innovation-led differentiation. Organizations that successfully combine premium product development, connected-device integration, and direct-to-patient distribution models will be best positioned to sustain growth and defend margins through 2031.
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/us-pen-needles-market-9759386.html